Atianzar Kimberly, Zhang Ming, Newhart Zachary, Gafoor Sameer
Medical College of Georgia at Augusta University Augusta, GA, US.
Swedish Heart and Vascular Institute Seattle, WA, US.
Interv Cardiol. 2019 Feb;14(1):45-47. doi: 10.15420/icr.2018.40.1.
In 2018, the world of functional mitral regurgitation changed with the presentation of two trials - Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation (MITRA-FR) and Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT). The trials, which seemed to point in two different directions, raised significant questions for the field. This article looks at the differences in effective regurgitant area, guideline-directed medical therapy, patient selection, technical clues and other reasons why the trials had similar aims but very different findings.
2018年,功能性二尖瓣反流领域发生了变化,两项试验——重度继发性二尖瓣反流患者经皮二尖瓣修复术MitraClip装置多中心研究(MITRA-FR)和心力衰竭合并功能性二尖瓣反流患者MitraClip经皮治疗的心血管结局评估(COAPT)公布了结果。这两项试验似乎指向两个不同的方向,给该领域带来了重大问题。本文探讨了有效反流面积、指南指导的药物治疗、患者选择、技术要点以及为何这两项试验目标相似但结果却大相径庭的其他原因。